Mainstream genetic testing for women with ovarian cancer provides a solid basis for patients to make a well-informed decision about genetic testing

[1]  R. Zweemer,et al.  Positive experiences of healthcare professionals with a mainstreaming approach of germline genetic testing for women with ovarian cancer , 2021, Familial Cancer.

[2]  K. Offit,et al.  Uptake and acceptability of a mainstreaming model of hereditary cancer multigene panel testing among patients with ovarian, pancreatic, and prostate cancer , 2021, Genetics in Medicine.

[3]  R. Kim,et al.  A Comparison of Patient-Reported Outcomes Following Consent for Genetic Testing Using an Oncologist- or Genetic Counselor-Mediated Model of Care , 2021, Current oncology.

[4]  J. K. Joseph,et al.  Oncologist-led BRCA counselling improves access to cancer genetic testing in middle-income Asian country, with no significant impact on psychosocial outcomes , 2021, Journal of Medical Genetics.

[5]  E. Kohn,et al.  PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  L. Kushi,et al.  Streamlining genetic testing for women with ovarian cancer in a Northern California health care system. , 2020, Gynecologic oncology.

[7]  S. Pignata,et al.  The forefront of ovarian cancer therapy: update on PARP inhibitors. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  L. Horvath,et al.  Mainstream consent programs for genetic counseling in cancer patients: A systematic review , 2020, Asia-Pacific journal of clinical oncology.

[9]  N. Rahman,et al.  Oncologist-led BRCA ‘mainstreaming’ in the ovarian cancer clinic: A study of 255 patients and its impact on their management , 2020, Scientific Reports.

[10]  A. Karsan,et al.  Oncology Clinic-Based Hereditary Cancer Genetic Testing in a Population-Based Health Care System , 2020, Cancers.

[11]  E. Kohn,et al.  Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Ledermann,et al.  Mainstreamed genetic testing in ovarian cancer: patient experience of the testing process , 2019, International Journal of Gynecological Cancer.

[13]  E. Smets,et al.  Genetic counseling of patients with ovarian carcinoma: acceptance, timing, and psychological wellbeing , 2019, Journal of Community Genetics.

[14]  M. C. Vos,et al.  Universal Tumor DNA BRCA1/2 Testing of Ovarian Cancer: Prescreening PARPi Treatment and Genetic Predisposition , 2019, Journal of the National Cancer Institute.

[15]  R. Kim,et al.  Next-Generation Service Delivery: A Scoping Review of Patient Outcomes Associated with Alternative Models of Genetic Counseling and Genetic Testing for Hereditary Cancer , 2018, Cancers.

[16]  Gloria S. Huang,et al.  Evaluation of a Streamlined Oncologist-Led BRCA Mutation Testing and Counseling Model for Patients With Ovarian Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Munsell,et al.  A universal genetic testing initiative for patients with high-grade, non-mucinous epithelial ovarian cancer and the implications for cancer treatment. , 2017, Gynecologic oncology.

[18]  S. Seal,et al.  Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients , 2016, Scientific Reports.

[19]  M. Maganti,et al.  The sooner the better: Genetic testing following ovarian cancer diagnosis. , 2015, Gynecologic oncology.

[20]  A. Dahl,et al.  Psychological distress related to BRCA testing in ovarian cancer patients , 2015, Familial Cancer.

[21]  K. Metcalfe,et al.  The influence of dispositional optimism on decision regret to undergo major breast reconstructive surgery , 2013, Journal of surgical oncology.

[22]  M. Friedlander,et al.  Communication and information needs of women diagnosed with ovarian cancer regarding treatment-focused genetic testing. , 2013, Oncology nursing forum.

[23]  R. van Hillegersberg,et al.  Behavioral and psychosocial effects of rapid genetic counseling and testing in newly diagnosed breast cancer patients: Design of a multicenter randomized clinical trial , 2011, BMC Cancer.

[24]  J. Boyages,et al.  Association of information satisfaction, psychological distress and monitoring coping style with post‐decision regret following breast reconstruction , 2007, Psycho-oncology.

[25]  Deb Feldman-Stewart,et al.  Validation of a Decision Regret Scale , 2003, Medical decision making : an international journal of the Society for Medical Decision Making.

[26]  T. T. Haug,et al.  The validity of the Hospital Anxiety and Depression Scale. An updated literature review. , 2002, Journal of psychosomatic research.

[27]  S. Sutton,et al.  Changes in psychological distress after cancer genetic counselling: a comparison of affected and unaffected women , 2002, British Journal of Cancer.

[28]  I. Varekamp,et al.  The decisional conflict scale: further validation in two samples of Dutch oncology patients. , 2001, Patient education and counseling.

[29]  J. Ormel,et al.  A validation study of the Hospital Anxiety and Depression Scale (HADS) in different groups of Dutch subjects , 1997, Psychological Medicine.

[30]  A. O'Connor.  Validation of a Decisional Conflict Scale , 1995, Medical decision making : an international journal of the Society for Medical Decision Making.

[31]  R. Snaith,et al.  The Hospital Anxiety And Depression Scale , 2003, Health and quality of life outcomes.

[32]  M. Clark,et al.  NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY Distress Management, Version 3.2019 , 2019 .

[33]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[34]  E. Legius,et al.  Communication with close and distant relatives in the context of genetic testing for hereditary breast and ovarian cancer in cancer patients , 2003, American journal of medical genetics. Part A.